Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

We're maintaining our Novo Nordisk fair value estimate at $89 per ADR. We expect Novo to gain $65 billion of a $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of ...

Novo’s oral version, Rybelsus, became another effective addition to its portfolio, while legacy insulin brands like NovoLog and Tresiba helped the company maintain its dominance in diabetes care.

However, total revenues missed the Zacks Consensus Estimate of $11.33 billion. Novo Nordisk also trimmed its sales growth guidance to 13-21% in 2025 from the 16-24% expected growth announced earlier.

Ellison says the settlement requires Novo Nordisk to provide insulin products—including Novolog, Tresiba, Fiasp, and Novolin, at any formulation and via any delivery method—at $35 per monthly ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new prices will go into effect on January 1, 2026.

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin ...

Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.

In the separate 78-week study enrolling patients who had previously received basal insulin, efsitora was compared to Tresiba, a once-daily insulin from Novo Nordisk. Lilly said its once-weekly ...

Arguably the biggest future rivalry between Novo Nordisk and Vertex, though, could be in the type 1 diabetes market. Novo markets several insulin products, including Fiasp, Levimir, and Tresiba.

As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them By Elaine Chen Reprints Arden Parrish at his home in Skokie, Ill. Eddie Quinones for STAT ...